Ines Nikolovski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2725260/publications.pdf

Version: 2024-02-01

17	517	11	17
papers	citations	h-index	g-index
18	18	18	773
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	21.4	136
2	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nature Cancer, 2022, 3, 723-733.	13.2	82
3	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2910-2919.	7.0	45
4	Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdominal Radiology, 2018, 43, 169-178.	2.1	44
5	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Scientific Reports, 2020, 10, 17769.	3.3	35
6	MRI of Tumors and Tumor Mimics in the Female Pelvis: Anatomic Pelvic Space–based Approach. Radiographics, 2019, 39, 1205-1229.	3.3	28
7	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. Gynecologic Oncology, 2020, 158, 608-613.	1.4	23
8	Imaging of Small Renal Masses before and after Thermal Ablation. Radiographics, 2019, 39, 2134-2145.	3.3	19
9	Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease. Gynecologic Oncology, 2019, 154, 72-76.	1.4	16
10	NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. Radiology, 2020, 297, 225-234.	7.3	15
11	Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?. Gynecologic Oncology, 2019, 155, 192-200.	1.4	14
12	Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study. Cancer Imaging, 2021, 21, 24.	2.8	13
13	Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. Journal of Urology, 2021, 205, 1055-1062.	0.4	12
14	Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes. Radiology, 2022, 302, 595-602.	7.3	12
15	A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecologic Oncology, 2021, 160, 71-76.	1.4	9
16	MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy. Clinical Genitourinary Cancer, 2022, , .	1.9	6
17	CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know— <i>Radiology</i> In Training. Radiology, 2022, 304, 516-526.	7.3	4